Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Código QR

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known to reduce low-density lipoprotein (LDL)-chole...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Henri K Parson, Meredith A Bundy, Charlotte B Dublin, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c3f5e8044c7f43f98bc197db1d733593
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
por: Parson H
Publicado: (2010)

Aerobic training increases skin perfusion by a nitric oxide mechanism in type 2 diabetes
por: Sheri R Colberg, et al.
Publicado: (2010)

Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study
por: Hernández-Ojeda J, et al.
Publicado: (2014)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Joshua J Neumiller, et al.
Publicado: (2010)

Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
por: Alaa Badawi, et al.
Publicado: (2010)

Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
por: Nanne Kleefstra, et al.
Publicado: (2009)

Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England
por: Stephen CL Gough, et al.
Publicado: (2009)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Michael A Via, et al.
Publicado: (2010)

TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Shitalkumar P Zambad, et al.
Publicado: (2011)

Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions
por: Angel Rodr&iacute;guez, et al.
Publicado: (2010)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: Al Sifri S
Publicado: (2012)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: AlMaatouq MA
Publicado: (2012)

Saxagliptin for type 2 diabetes
por: Antonio R Chacra, et al.
Publicado: (2010)

Optimizing weight control in diabetes: antidiabetic drug selection
por: S Kalra, et al.
Publicado: (2010)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Effect of Holostemma annularis on the progression of diabetes induced by a high fructose diet in rats and in diabetic C57BL/6J ob/ob mice
por: Sudharshan Reddy D, et al.
Publicado: (2010)

Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes
por: Priyanka Gunasekara, et al.
Publicado: (2011)

Type 2 diabetes in Brazil: epidemiology and management
por: Almeida-Pititto B, et al.
Publicado: (2015)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell DR, et al.
Publicado: (2015)

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing
por: Satyanarayana Medicherla, et al.
Publicado: (2009)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Gregory E Peterson
Publicado: (2009)

Linking obesity with type 2 diabetes: the role of T-bet
por: Wali JA, et al.
Publicado: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Giuseppe Derosa, et al.
Publicado: (2009)

Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-&kappa;B suppression
por: Sirada Rungseesantivanon, et al.
Publicado: (2010)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
por: Madden KM
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

AMPK activation: a therapeutic target for type 2 diabetes?
por: Coughlan KA, et al.
Publicado: (2014)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Red cell distribution width in type 2 diabetic patients
por: Nada AM
Publicado: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDENCE Study
por: Rinkoo Dalan, et al.
Publicado: (2010)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Paul Valensi
Publicado: (2009)

A psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R) cognitive distress, fatigue, hyperglycemia, and hypoglycemia subscales in patients with type 1 and type 2 diabetes
por: April N Naegeli, et al.
Publicado: (2010)

Expression of gluconeogenic enzymes and 11β-hydroxysteroid dehydrogenase type 1 in liver of diabetic mice after acute exercise
por: Brust KB, et al.
Publicado: (2014)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
por: Dara P Schuster
Publicado: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
por: Anderson M, et al.
Publicado: (2014)